Context: Despite the well-recognized clinical features resulting from insufficient or excessive thyroid hormone (TH) levels in humans, it is largely unknown which genes are regulated by TH in human tissues.
T hyroid hormone (TH) affects virtually all cells and tissues in the human body. The major biologically active TH is T3, and its genomic actions are mediated by binding to nuclear T3 receptors (TRs) that regulate transcription of target genes (1) . Several receptor isoforms are encoded by the THRA and THRB genes of which TRa1, TRb1, and TRb2 are the truly T3 binding isoforms (2) . The TR isoforms have a distinct expression pattern, with a predominance of TRa1 in brain, heart, and bone and TRb1 in the liver, kidney, and thyroid. TRb2 is mainly expressed in the hypothalamus and pituitary and is therefore involved in the regulation of the hypothalamus-pituitary-thyroid axis (3) .
Despite the classical clinical features resulting from insufficient or excessive TH levels that have been recognized for more than 100 years, the underlying molecular mechanisms in humans are not well understood. Knowledge of gene expression modulated by TH is largely derived from animal models or in vitro cellular studies used to explore which genes are regulated by TH (4) (5) (6) (7) . Expanding knowledge of the effects of TH on gene expression in human tissues will provide more insight in the molecular basis of TH action and may lead to a better understanding of the clinical effects of TH in humans.
Progress is limited because most human tissues are not easily accessible. However, blood can be regarded as circulating tissue and contains various cell types including erythrocytes, leukocytes, and platelets (8) . RNA in whole blood is largely determined by leukocytes. Peripheral blood mononuclear cells (lymphocytes and monocytes) have been shown to mainly express the TRa isoform (9) . Therefore, analysis of gene expression in whole blood may potentially be used as proxy for other TRaexpressing tissues. To study the effects of TH on gene expression in human TRa-expressing cells, we performed next-generation RNA sequencing (RNA-seq) in whole blood cells from athyroid patients off and on levothyroxine (LT4) treatment.
Patients and Methods

Patients
Patients were recruited via the outpatient clinic of the Erasmus Medical Center, which is a tertiary referral center for differentiated thyroid cancer (DTC). Patients with DTC undergoing thyrotropin (TSH)-stimulated 131 I therapy after withdrawal of LT4 were asked to participate in the study. Patients were eligible for inclusion if they had no other malignancies or an active inflammatory disease, were not using any drugs known to influence TH metabolism, and were between 18 and 80 years of age. A discovery and a validation cohort were created according to the same protocol.
The study protocol was approved by the Medical Ethics Committee of the Erasmus Medical Center (MEC 2012-561). Written informed consent was obtained from all study participants.
Sample collection and serum analyses
Peripheral blood samples were obtained from all participants when overt biochemical hypothyroidism was achieved by withdrawal of LT4 substitution in thyroidectomized patients and when TSH suppression was achieved after restarting LT4 replacement therapy. Serum free T4 (reference range, 11 to 25 pmol/L), total T4 (reference range, 58 to 128 nmol/L), and total T3 (reference range, 1.4 to 2.5 nmol/L) concentrations were measured by chemoluminescence assays (Vitros ECI Immunodiagnostic System; Ortho-Clinical Diagnostics, Rochester, MI). Serum TSH (reference range, 0.4-4.3 mU/L) was measured by an immunometric assay (Immulite 2000 XPi; Siemens, Den Haag, the Netherlands). Whole blood samples were collected in PAXgene tubes (Hombrechtikon, Switzerland). PAXgene tubes contain a proprietary reagent that immediately stabilizes intracellular messenger RNA (mRNA), thus reducing mRNA degradation and inhibiting gene induction after phlebotomy. The isolated mRNA represents all blood cells, including polymorph nuclear leukocytes, mononuclear cells, platelets and red blood cells (10) .
RNA was isolated using PAXgene blood miRNA kits (PreAnalytiX, Hombrechtikon). For RNA-seq analysis of the discovery cohort, ribosomal RNA and globin mRNAs were removed from an aliquot of the RNA samples using the GlobinZero Gold rRNA Removal Kit (Illumina, San Diego, CA) (11) . Kapa Stranded RNA library was prepared (Kapa Stranded RNA kit; Kapa Biosystems, Wilmington, MA), followed by sequencing on a HiSeq2500 system, for single end reads, 50 bp in length (Illumina, San Diego, CA).
Bioinformatic analysis
We analyzed genes with at least five reads in at least six samples. The generated sequencing reads were aligned (stranded alignment) against the GRCh38 version of the human reference genome, with RefSeq gene annotation using Tophat2 (12) . Gene counts were generated from the BAM files with HTsEquation (13) . Cufflinks was used to compute transcript abundance estimates in fragments per kilobase of transcript per million mapped reads (FPKMs) (14) . Differential expression was calculated with the bioinformatics tool DESEquation 2 from Bioconductor, which uses the R statistical programming language (15) . Cutoff values for significantly expressed genes were a false discovery rate of 0.05 or less and a fold change of 1.5. To visualize the clustering of the samples, principal component analysis was performed. The normalized data file was transposed and imported into OmniViz, version 6.1.13 (Instem Scientific, Inc., Stone, Staffordshire, UK), for further analysis. The geometric mean of the intensity of all samples was calculated. The level of expression of each gene was determined relative to this geometric mean and 2 log transformed. The geometric mean of all samples was used to ascribe equal weight to gene expression levels with similar relative distances to the geometric mean. The data were deposited in National Center for Biotechnology Information/Gene Expression Omnibus reference (https://www.ncbi.nlm.nih.gov/geo/) with accession number GSE103305.
We used functional enrichment analysis to explore the biological significance of differentially expressed (DE) genes and of weighted gene coexpression network analysis (WGCNA) module genes (see the following section) using Database for Annotation, Visualization, and Integrated Discovery (Expression Analysis Systemic Explorer) (16) , which calculates significantly overrepresentation of gene ontology (GO)-classified biological processes by comparing the number of genes in a gene list for a biological process to the number of genes for that biological process from the RNA-seq analysis (17) . Biological processes are shown that were significantly enriched after correction for multiple testing.
The independent skeletal muscle dataset for comparative analysis consisted of 10 thyroidectomized patients with DTC 4 weeks after LT4 withdrawal (before TSH-stimulated 131 I scintigraphy) and 8 weeks after subsequent LT4 replacement (18) .
To study the expression of the TR isoforms in different blood cell types, independent datasets on RNA-seq in platelets (National Center for Biotechnology Information Sequence Read Archive SRP028846), lymphocytes (E-MTAB-2319), and neutrophils (Gene Expression Omnibus Series GSE59528) were collected from previous studies (19) (20) (21) . FPKM values of TRa1 and TRb1 in the different cell types were compared using a t test.
Quantitative polymerase chain reaction
To confirm the RNA-seq results by an independent technique, quantitative polymerase chain reaction (qPCR) was used to measure expression of selected genes. qPCR was performed on complementary DNA produced from RNA before applying Globin-Zero Gold rRNA Removal Kits on the discovery cohort and on complementary DNA from the validation cohort. The primer sequences are presented in Supplemental Table 1 . RNA levels are expressed relative to the geometric mean of the housekeeping genes GAPDH and ACTB.
Statistical analysis
Likelihood and significance of the overlap with DE genes in muscle samples off and on LT4 treatment previously reported were tested using the x2 test (18) . Thyroid function tests and leukocyte counts were compared off and on LT4 treatment using the Wilcoxon signed-rank test. FPKM values of the TRa1 gene were compared off and on LT4 using a paired t test. Statistical analysis was performed using SPSS Statistics for Windows, version 22 (IBM Corp., Armonk, NY).
WGCNA
We performed a WGCNA to discover coexpressed THrelated networks (modules) (22, 23) . In short, a weighted adjacency matrix containing pairwise connection strengths was constructed by using the soft-thresholding approach (b = 6) on the matrix of pairwise correlation coefficients. A connectivity measure (k) per gene was calculated by summing the connection strengths with other genes. Modules were defined as branches of a hierarchical clustering tree using a dissimilarity measure (1, topological overlap matrix) (23, 24) . Each module was subsequently assigned a color. The gene expression profiles of each module were summarized by the module eigengene (defined as the first principal component of the module expression levels). Each module eigengene was correlated to thyroid status (with age, body mass index, sex, leukocytes, and leukocyte differentiation as covariates) using the WGCNA R package (false discovery rate, 5%).
Results
Study population
We studied whole blood samples from eight athyroid patients (four females and four males) off and on LT4 treatment. Characteristics of the patients are shown in Supplemental Table 2 . Table 1 shows the serum TH concentrations and total leukocyte counts, including leukocyte differentiation, off and on LT4 treatment. As expected, the thyroid function tests were significantly different. Neither total leukocyte counts nor leukocyte differentiation showed substantial differences, except for a slight increase in monocyte number during LT4 treatment.
Standard gene expression analysis
To assess the effects of thyroid state on gene expression in whole blood cells, we performed next-generation RNAseq on samples drawn from patients off and on LT4 replacement therapy. At least 15 million reads were generated for each sample, and approximately 95% of these reads were aligned. We first quantified both TR isoforms to confirm that TRa is the main receptor isoform expressed in whole blood samples (Fig. 1A) . TRa1 expression appeared reduced during LT4 therapy compared with the hypothyroid state (P = 0.008). TRa1 expression quantified by qPCR analysis also showed a trend toward downregulation, although this failed to reach statistical significance (Supplemental Fig. 1) . Reanalysis of the TR isoforms in different blood cell types of independent datasets showed that TRa1 expression was much higher than TRb1 in platelets, lymphocytes, and neutrophils, suggesting that TRa1 is indeed the major TR isoform expressed in whole blood (Supplemental Fig. 2) (19-21) .
After filtering for expressed genes, 16,014 genes remained for analysis. Principal component analysis showed a high degree of clustering of patients off and on LT4 treatment. We detected 1227 DE genes (multiple testing corrected P value , 0.05). We selected 486 DE genes with an absolute fold-change .1.5 (Supplemental Table 3 ), shown as hierarchical clustering in Fig. 1B . This indicates that thyroid state has both positive and negative effects on gene regulation (76% upregulated; 24% downregulated). The 47 genes that differed at least twofold in expression are presented in Table 2 .
Validation of selected genes
To validate the RNA-seq data from the discovery cohort, qPCR was used as an independent technique to measure the relative expression of selected DE genes. Genes were selected based on robust baseline expression, robust fold change in expression, and low adjusted P value. All upregulated and most downregulated genes showed substantial differential expression using qPCR (Fig. 2) . We validated our findings in an independent cohort; the baseline characteristics are shown in Supplemental Table 4 . qPCR analysis of the validation cohort confirmed that all genes were similarly regulated by TH as in the discovery cohort, although this was not substantial for some small nucleolar RNAs (snoRNAs) and phosphodiesterase 5A (Fig. 2) .
GO analysis
Next, we analyzed whether the 486 DE genes were associated with specific biological processes. GO enrichment analysis revealed that seven biological processes were significantly overrepresented after correction for multiple testing (false discovery rate, 0.05) (Supplemental Table 5 ). Because some GO terms overlapped based on similar groups of genes, the number of biological processes was reduced to three (Fig. 3) .
Comparative transcriptome analysis
To explore to which extent gene expression in whole blood parallels gene expression in other tissues, we investigated the overlap with gene expression in skeletal muscle in different thyroid states (18) . This dataset contained 607 DE genes (fold-change .1.5) in muscle samples off and on LT4 treatment as previously reported. Comparative transcriptome analysis of the 486 DE genes (foldchange .1.5) of the current study with the muscle dataset revealed 26 genes that were shared between both tissues, which is a significant 2.3-fold enrichment (P = 4.1 3 10 25 ) (Supplemental Table 6 ). Of these 26 shared genes, 6 were regulated in the opposite direction. If removed from the analysis, this resulted in a 1.7-fold enrichment (P = 0.02).
WGCNA
To further explore TH-dependent transcriptional patterns in the current dataset, we used WGCNA analysis. WGCNA can reveal the underlying organization of the transcriptome based on coexpression relationships. WGCNA complements traditional DE analyses by providing a system level framework for the understanding of transcriptional profiles. This has been shown particularly helpful in transcriptome analysis of samples composed of distinct cell and tissue types (25) .
Therefore, WGCNA is potentially useful to identify specific cell types responsive to different thyroid states. First, the genes showing most variability between samples (i.e., at least a 2.0-fold change in level of expression from the global mean) were selected. This resulted in 6649 genes, which were determined by their coefficient of variance, rather than any sample characteristics such as disease status. Subsequently, unsupervised hierarchical clustering led to the identification of 17 coexpression modules (Fig. 4A) . Modules correspond to branches and are color-coded, ranging in size from 67 genes in the light cyan module to 1737 in the turquoise module (Supplemental Table 7 ). Next, modules were identified that were significantly associated with clinical parameters, including age, sex, leukocytes, and thyroid state. Therefore, the summary file (eigengene) for each module was correlated with the clinical parameters to select the most relevant associations (Fig. 4B) . The strength of WGCNA analysis is well exemplified by the tan module. The unbiased approach identified 120 genes in this module, which were closely linked according to WGCNA. Subsequent inspection learned that this module mainly contained genes expressed from the Y-chromosome. Regression analysis afterward correctly identified (male) sex to this module (r = 0.97, P = 2.0 3 10
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). Using a similar analysis, the blue and the midnight blue modules were significantly associated with thyroid state. The blue module correlated positively with thyroid state (r = 0.65, P = 0.007) and contained numerous genes (213 of the 814 genes in this module) that were also found significantly regulated by TH in the DE analysis. The positive correlation reflects that most blue module genes were upregulated by TH.
Next, we performed a GO enrichment analysis for the genes in the blue module (Supplemental Table 5 ). The biological process hemostasis was significantly enriched in the blue module. Of note, many genes in the blue module appeared transcripts expressed in platelets (e.g., P2RY12 and PF4). The module midnight blue was negatively correlated with thyroid state (r = 20.78, genes) that were regulated by TH as well in the DE analysis, of which 26 (75%) were downregulated. Many genes in the module midnight blue belonged to the class of snoRNAs and contained mostly genes without a GO annotation. Thus, WGNCA analysis suggested that gene expression not only in leukocytes but also in platelets is dependent on thyroid state.
Discussion
In humans, genes that are regulated by thyroid state are largely unknown. Previously, we and others discovered genes that are dependent on thyroid state in human skeletal muscle (18, 26) . Ex vivo studies have identified T3-responsive genes in human skin fibroblasts and adipocytes (26) (27) (28) . The current study identifies numerous genes in human whole blood samples that are regulated by thyroid state. Similar to previous transcriptome analysis studies, TH largely positively regulates gene expression, although a considerable number of genes is downregulated. Because RNA from leukocytes is a major determinant to total RNA in blood (after removal of globin RNA), it is likely that the detected DE genes largely represent the effects of thyroid state on leukocytes.
To improve the yield of our genome-wide expression profiling, we performed WGCNA and compared these results with those of a standard analysis based on differential expression. Although a standard analysis typically discloses lists of DE genes, it fails to recognize the different connections between them. Indeed, WGCNA mapped many genes related to thyroid state into two large coexpression modules (modules blue and midnight blue). GO enrichment analyses of the TH-associated module blue showed predominance of the biological process hemostasis of which the involved genes were upregulated by TH. Of note, many genes were platelet specific transcripts (e.g., P2RY12 and PF4). Because platelets are anucleate, their mRNA content derives from nucleate precursors, which is translated into proteins (29) . The product of P2RY12 is a purinergic G-protein coupled receptor, which plays a crucial role in thrombus formation (30) . P2RY12 inhibitors, such as clopidogrel and ticagrelor, have antithrombotic effects and are widely used in patients with acute coronary syndromes and in the secondary prevention of thrombotic events in vascular diseases (31) . PF4 codes for a chemokine (platelet factor 4), which is synthesized in megakaryocytes and stored in platelet alpha granules. When platelets are activated, PF4 is released from the alpha granules facilitating thrombosis (32) . The observation that circulating PF4 levels are decreased in patients with subclinical autoimmune hypothyroidism supports our findings (33) . F13A1, another upregulated gene by TH, encodes the coagulation factor XIIIA subunit. Coagulation factor XIII is important for stabilization of the fibrin clot. Pietzner et al. recently demonstrated that thyrotoxicosis increased the levels of several coagulation cascade proteins, including coagulation factors IX, XI, and XIII in plasma (34) . Together, these data suggest that TH induces transcription of prothrombotic genes. This is in line with the observation that hyperthyroidism increases the risk of thrombosis (35, 36) . Even high-normal thyroid function within the reference range is associated with stroke, independent of classical cardiovascular risk factors (37) . Previously, it has been shown that the production of several coagulation factors produced in the liver is enhanced by TH (38, 39) . Although we were unable to assess thrombocyte counts, other studies have demonstrated that platelet number is independent of thyroid state (40) . The current study suggests that increased TH levels also positively regulate prothrombotic factors in platelets.
The second WGCNA module that correlated negatively with thyroid state was mainly composed of snoRNAs that were mostly downregulated by TH. snoRNAs are classified into two families (box C/D and box H/ACA) and are required for posttranscriptional modifications of ribosomal RNA (41) . Because the relationship between snoRNAs and TH has not been reported before, further studies are needed to understand the consequences of this finding.
Although the effects of thyroid state on peripheral blood cells (leukocytes, platelets) are of interest (see the previous section), we explored to which extent those findings were relevant for other tissues. Because whole blood samples mainly contain TRa-expressing cells, our results putatively reflect the effect of TH on gene expression via TRa. Because TRa is abundantly expressed over TRb in skeletal muscle, we sought to determine overlap between genes dependent on TH in muscle and genes identified in the current study. The overlap with the DE genes from our previous study in muscle samples was small but statistically significant. This finding suggests that a subset of genes is commonly regulated by TRa1 in various tissues. A few of those genes were regulated in the opposite direction. Although counterintuitive, this phenomenon has been described before (e.g., the well-known T3-responsive gene Reelin) (42) . However, the lack of a large overlap also indicates that thyroid state affects different genes in different tissues. Together, these findings may limit the use of whole blood samples as a proxy for the effects of TH on other TRa-expressing tissues in humans (18) .
Several strengths and limitations are worth mentioning to provide context to our findings. A first limitation is that the observed changes in gene expression may not necessarily reflect direct effects of TH. Gene transcription may also be indirectly dependent on TH if it modulates intermediate signaling molecules. Our studies thus reflect the net effect on gene expression upon changes in thyroid state. In this context, it is worth mentioning the somewhat conflicting results on the limited downregulation of TRa1 in the RNA-seq analysis, which is in line with a previous study that observed a downregulation of TRa1 in hematopoietic progenitor cells obtained from the peripheral blood of hyperthyroid patients compared with a euthyroid control group, although qPCR quantification failed to reach statistical significance (43) . These observations suggest that the expression of TRa1 in peripheral blood cells is negatively dependent on thyroid state, possibly dampening the effect size of changes in thyroid state. Second, whole blood contains many different cell types. Although WGCNA was relevant in this context, other subtle changes may have gone unrecognized. Third, DE genes in hypothyroid vs mild thyrotoxic state (as in this study) are not necessarily the same DE genes as in hyperthyroid vs mild thyrotoxic state. Finally, because the patients adhered to an iodine deficient diet at the time of hypothyroidism, direct effects of changes in iodine state on gene expression cannot be excluded. Our study has several strengths. First, the study design included paired analyses, which has the advantage to reduce confounders and variability. Second, the results were confirmed in an independent cohort, substantiating the robustness of our findings. Third, we were able to study extreme differences in thyroid state in human subjects without thyroid autoimmunity.
In conclusion, we demonstrate that thyroid state regulates numerous genes in human whole blood. Furthermore, we found that thyroid state affects gene transcripts in platelets, which contributes to the understanding of thrombosis in hyperthyroidism. The overlap with previously reported DE genes in muscle samples indicate that a subset of genes is commonly regulated in TRa-expressing tissues in humans. Future studies should explore if specific transcripts in whole blood can be useful biomarkers for tissue-specific thyroid state.
